211:), a naturally occurring isoform of vimentin to optimize the performance of the test. Noteworthy are the findings of a recently published study that highly valuates anti-MCV test systems for diagnosing rheumatoid arthritis in anti-CCP-negative patients. However, data from all around the world vary substantially. Anti-CCP is also very useful in the early diagnosis of rheumatoid arthritis in high-risk groups, such as relatives of RA patients, although Silman and co-workers found that the concordance rate of developing RA was 15.4% among identical (monozygotic) twins and was 3.6% among fraternal (dizygotic) twins.
43:
33:
304:
and make up the citrullinome continues to increase. The RA associated citrullinome has been reported to include targets from synovial fluid and tissue that range from proteases, receptors, and carrier proteins. These proteins are components of complement, proteolytic activity, cell recognition,
153:, which is a member of the intermediate filament family of proteins. Several assays for detecting ACPAs were developed in the following years, employing mutated citrullinated Vimentin (MCV-assay), filaggrin-derived peptides (CCP-assay) and viral citrullinated peptides (VCP-assay).
903:
Greiner A, Plischke H, Kellner H, Gruber R (June 2005). "Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis".
167:
represent a discriminating specific marker of rheumatoid arthritis from other chronic arthritides and disease controls, suggesting an independent production of each isotype. In 2010, ACPA testing has become substantial part of
1315:
Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, Gill G, Meyer O, Dieudé P (October 2014). "High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis".
148:
was investigated. Subsequent studies demonstrated that autoantibodies from RA patients react with a series of different citrullinated antigens, including fibrinogen, deiminated
Epstein-Barr Virus Nuclear Antigen 1 and
630:
Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (March 2006). "Deiminated
Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis".
214:
Given that ACPA are more specific than rheumatoid factor, they are used to distinguish various causes of arthritis. Novel assays may be useful for monitoring disease activity and effects of RA therapy.
1068:
Iwaszkiewicz C, Puszczewicz M, Białkowska-Puszczewicz G (January 2015). "Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis".
717:
Nishimura K, Sugiyama D, Kogata Y, et al. (June 2007). "Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis".
140:
The presence of autoantibodies against citrullinated proteins in rheumatoid arthritis patients was first described in the mid-1970s when the biochemical basis of antibody reactivity against
292:) not only enhances the diagnostic capture rate but together with acute phase reactants either in early disease or at the time of diagnosis may be useful in predicting future outcomes.
83:. Clinically, cyclic citrullinated peptides (CCP) are frequently used to detect these antibodies in patient serum or plasma (then referred to as anti–citrullinated peptide antibodies).
203:. Vimentin is secreted and citrullinated by macrophages in response to apoptosis, or by pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha). A newly developed
199:
However, novel test systems utilizing ACPA have been developed. Citrullinated vimentin is a very promising autoantigen in RA, and a suitable tool for studying this systemic
378:
Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT (2007). "Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts".
807:
762:"IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders"
823:"Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis"
666:
Bang H, Egerer K, Gauliard A, et al. (August 2007). "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis".
1648:
947:
Asaga H, Yamada M, Senshu T (February 1998). "Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages".
1238:"Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy"
1445:
1152:
Silman AJ, MacGregor AJ, Thomson W, et al. (October 1993). "Twin concordance rates for rheumatoid arthritis: results from a nationwide study".
426:"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative"
277:. Anti-CCP positivity is also a good prognostic marker for future radiographic damage, and possibly a marker to B-cell therapy responses including
425:
1598:
1189:"Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review"
1653:
129:
1687:
1627:
1478:
219:
1113:"Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil"
1026:
583:
527:"The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies"
1737:
208:
196:(RF). Moreover, analysis of the correlation of anti-CCP antibody titre with RA disease activity yielded conflicting results.
1505:
1298:
1438:
1643:
1615:
1578:
1570:
1515:
1498:
1351:
Tilvawala R, Nguyen SH, Maurais AJ, Nemmara VV, Nagar M, Salinger AJ, Nagpal S, Weerapana E, Thompson PR (June 2018).
300:
Vimentin, fibrin, filaggrin, enolase and keratin are common citrullination targets. The list of proteins that undergo
982:
Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (January 2003). "Vimentin is secreted by activated macrophages".
1546:
1530:
1111:
Goeldner, I.; Skare, T. L.; De
Messias Reason, I. T.; Nisihara, R. M.; Silva, M. B.; Utiyama, S. R. (August 2010).
761:
1732:
1471:
760:
C. Anzilotti; L. Riente; F. Pratesi; D. Chimenti; A. Delle Sedie; S. Bombardieri; P. Migliorini (October 2007).
1669:
704:
1535:
1758:
1692:
1560:
1431:
766:
1620:
1488:
1462:
700:
1703:
274:
164:
121:
80:
864:"The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis"
1674:
1483:
90:
17:
1400:
Maksymowych WP, Marotta A (2014). "14-3-3η: a novel biomarker platform for rheumatoid arthritis".
331:"Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis"
1093:
1007:
929:
742:
458:
403:
200:
185:
181:
128:
were introduced. These new classification criteria include ACPA testing, and overruled the "old"
1709:
1409:
1382:
1333:
1269:
1218:
1169:
1134:
1085:
1038:
999:
964:
921:
885:
844:
799:
791:
783:
734:
683:
648:
612:
556:
507:
450:
395:
360:
309:) is also another synovial derived protein that has been reported as a citrullination target.
285:
193:
1027:"Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis"
730:
1372:
1364:
1325:
1259:
1249:
1208:
1200:
1161:
1124:
1077:
991:
956:
913:
875:
834:
775:
726:
675:
640:
602:
592:
546:
538:
497:
489:
440:
387:
350:
342:
157:
1296:
chronolab.com > Autoantibodies associated with rheumatic diseases > Reference ranges
156:
A 2006 clinical study showed that anti viral citrullinated peptide (VCP) antibodies of the
1681:
1302:
110:
1377:
1352:
1264:
1237:
1213:
1188:
502:
477:
355:
330:
301:
102:
76:
60:
607:
578:
551:
526:
1752:
1165:
1097:
1046:
1011:
933:
1454:
1368:
746:
462:
407:
1129:
1112:
779:
192:, for example CCP-assays, they only provide a sensitivity comparable with that of
42:
1329:
839:
822:
880:
863:
579:"Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin"
189:
1295:
1553:
391:
94:
36:
795:
787:
1589:
1525:
1204:
1081:
917:
445:
346:
278:
145:
117:
1413:
1386:
1337:
1273:
1222:
1138:
1089:
1042:
1003:
960:
925:
889:
848:
803:
738:
687:
652:
616:
454:
399:
364:
1173:
968:
560:
493:
32:
1510:
511:
150:
106:
105:. If their shapes are significantly altered, the proteins may be seen as
98:
87:
64:
46:
862:
van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE (1 November 2005).
141:
72:
68:
679:
644:
542:
1608:
1603:
1236:
Nicaise Roland P, Grootenboer Mignot S, Bruns A, et al. (2008).
305:
endocytosis, and response to biotic stimuli amongst others. 14-3-3η (
188:
between 87.8% and 96.4%. Despite the excellent performance of these
1254:
995:
597:
273:
Anti-CCP is part of the 2010 ACR/EULAR classification criteria for
170:
The 2010 ACR-EULAR classification criteria for rheumatoid arthritis
476:
Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (July 1979).
306:
289:
204:
41:
31:
1423:
1427:
821:
Coenen D, Verschueren P, Westhovens R, Bossuyt X (March 2007).
180:
In a comparative study (in 2007), various detection kits had a
1520:
324:
322:
161:
424:
Aletaha D, Neogi T, Silman AJ, et al. (September 2010).
207:
system utilises genetically modified citrullinated vimentin (
284:
Combination of anti-CCP with other serological markers like
126:
2010 ACR/EULAR Rheumatoid
Arthritis Classification Criteria
67:
to an individual's own proteins) that are directed against
124:(RA) to be made at a very early stage. In July 2010, the
1025:
Soós L, Szekanecz Z, Szabó Z, et al. (August 2007).
577:
Vossenaar ER, Després N, Lapointe E, et al. (2004).
525:
Sebbag M, Simon M, Vincent C, et al. (June 1995).
79:. They are present in the majority of patients with
1725:
1662:
1636:
1587:
1569:
1461:
572:
570:
1353:"The Rheumatoid Arthritis-Associated Citrullinome"
478:"Anti-keratin antibodies in rheumatoid arthritis"
222:of anti–citrullinated protein antibodies are:
1439:
8:
1291:
1289:
1287:
1285:
1283:
1187:Avouac J, Gossec L, Dougados M (July 2006).
109:by the immune system, thereby generating an
1070:International Journal of Rheumatic Diseases
296:Other ACPAs and citrullinated targets in RA
1446:
1432:
1424:
329:Puszczewicz M, Iwaszkiewicz C (May 2011).
1376:
1263:
1253:
1212:
1128:
879:
838:
703:at the U.S. National Library of Medicine
606:
596:
550:
501:
444:
419:
417:
354:
731:10.7326/0003-4819-146-11-200706050-00008
224:
132:and are adapted for early RA diagnosis.
318:
53:Anti-citrullinated protein antibodies
7:
810:from the original on 30 August 2020.
93:can be enzymatically converted into
18:Anti-citrullinated protein antibody
25:
116:ACPAs have proved to be powerful
1242:Arthritis Research & Therapy
584:Arthritis Research & Therapy
220:reference ranges for blood tests
1369:10.1016/j.chembiol.2018.03.002
1166:10.1093/rheumatology/32.10.903
184:between 69.6% and 77.5% and a
1:
949:Biochem. Biophys. Res. Commun
97:residues in proteins such as
1330:10.1016/j.jbspin.2014.06.001
840:10.1373/clinchem.2006.078063
701:cyclic+citrullinated+peptide
120:that allow the diagnosis of
1599:Anti-neutrophil cytoplasmic
1571:Anti-mitochondrial antibody
1130:10.1093/rheumatology/keq134
881:10.4049/jimmunol.175.9.5575
780:10.1093/rheumatology/kem193
719:Annals of Internal Medicine
1775:
1715:Anti-citrullinated peptide
1305:Retrieved on 29 April 2010
1506:Anti-topoisomerase/Scl-70
392:10.1080/10408360701295623
705:Medical Subject Headings
1628:Anti-TPO/Antimicrosomal
1205:10.1136/ard.2006.051391
1082:10.1111/1756-185X.12544
918:10.1196/annals.1313.031
446:10.1136/ard.2010.138461
347:10.5114/aoms.2011.22067
1408:(5 Suppl 85): S–35–9.
961:10.1006/bbrc.1998.8148
101:, by a process called
49:
39:
1688:Anti-transglutaminase
1463:Anti-nuclear antibody
1117:Rheumatology (Oxford)
494:10.1136/bmj.2.6182.97
380:Crit Rev Clin Lab Sci
176:Clinical significance
86:During inflammation,
45:
35:
1301:30 July 2013 at the
906:Ann. N. Y. Acad. Sci
275:Rheumatoid Arthritis
244:High/strong positive
130:ACR criteria of 1987
122:rheumatoid arthritis
81:rheumatoid arthritis
1738:Anti-apolipoprotein
1675:Lupus anticoagulant
1049:on 20 February 2008
91:amino acid residues
1726:Multiple locations
1616:Anti-smooth muscle
1402:Clin Exp Rheumatol
201:autoimmune disease
50:
40:
1746:
1745:
1733:Anti-phospholipid
1710:Rheumatoid factor
1363:(6): 691–704.e6.
1154:Br J Rheumatology
680:10.1002/art.22817
645:10.1002/art.21629
543:10.1172/JCI117969
286:rheumatoid factor
271:
270:
239:Moderate positive
234:Low/weak positive
194:rheumatoid factor
16:(Redirected from
1766:
1695:not autoantibody
1644:Anti-ganglioside
1579:Anti-cardiolipin
1448:
1441:
1434:
1425:
1418:
1417:
1397:
1391:
1390:
1380:
1348:
1342:
1341:
1318:Joint Bone Spine
1312:
1306:
1293:
1278:
1277:
1267:
1257:
1233:
1227:
1226:
1216:
1184:
1178:
1177:
1149:
1143:
1142:
1132:
1108:
1102:
1101:
1065:
1059:
1058:
1056:
1054:
1045:. Archived from
1022:
1016:
1015:
979:
973:
972:
944:
938:
937:
900:
894:
893:
883:
859:
853:
852:
842:
818:
812:
811:
757:
751:
750:
714:
708:
698:
692:
691:
663:
657:
656:
627:
621:
620:
610:
600:
574:
565:
564:
554:
522:
516:
515:
505:
473:
467:
466:
448:
430:
421:
412:
411:
375:
369:
368:
358:
326:
225:
21:
1774:
1773:
1769:
1768:
1767:
1765:
1764:
1763:
1749:
1748:
1747:
1742:
1721:
1682:Coeliac disease
1658:
1632:
1583:
1565:
1547:Anti-centromere
1457:
1452:
1422:
1421:
1399:
1398:
1394:
1350:
1349:
1345:
1314:
1313:
1309:
1303:Wayback Machine
1294:
1281:
1235:
1234:
1230:
1193:Ann. Rheum. Dis
1186:
1185:
1181:
1151:
1150:
1146:
1110:
1109:
1105:
1067:
1066:
1062:
1052:
1050:
1024:
1023:
1019:
981:
980:
976:
946:
945:
941:
902:
901:
897:
861:
860:
856:
820:
819:
815:
774:(10): 1579–82.
759:
758:
754:
725:(11): 797–808.
716:
715:
711:
699:
695:
668:Arthritis Rheum
665:
664:
660:
633:Arthritis Rheum
629:
628:
624:
576:
575:
568:
531:J. Clin. Invest
524:
523:
519:
475:
474:
470:
433:Ann. Rheum. Dis
428:
423:
422:
415:
377:
376:
372:
328:
327:
320:
315:
298:
178:
138:
111:immune response
28:
23:
22:
15:
12:
11:
5:
1772:
1770:
1762:
1761:
1759:Autoantibodies
1751:
1750:
1744:
1743:
1741:
1740:
1735:
1729:
1727:
1723:
1722:
1720:
1719:
1718:
1717:
1712:
1699:
1698:
1697:
1696:
1690:
1678:
1677:
1672:
1666:
1664:
1660:
1659:
1657:
1656:
1654:Anti-glutamate
1651:
1646:
1640:
1638:
1634:
1633:
1631:
1630:
1625:
1624:
1623:
1613:
1612:
1611:
1606:
1595:
1593:
1585:
1584:
1582:
1581:
1575:
1573:
1567:
1566:
1564:
1563:
1557:
1556:
1550:
1549:
1543:
1542:
1541:
1540:
1539:
1538:
1533:
1528:
1523:
1513:
1508:
1494:
1493:
1492:
1491:
1486:
1481:
1467:
1465:
1459:
1458:
1455:Autoantibodies
1453:
1451:
1450:
1443:
1436:
1428:
1420:
1419:
1392:
1357:Cell Chem Biol
1343:
1307:
1279:
1255:10.1186/ar2570
1228:
1179:
1144:
1103:
1060:
1037:(8): 1658–63.
1017:
996:10.1038/ncb898
984:Nat. Cell Biol
974:
939:
895:
874:(9): 5575–80.
854:
833:(3): 498–504.
813:
752:
709:
693:
674:(8): 2503–11.
658:
622:
598:10.1186/ar1149
591:(2): R142–50.
566:
517:
488:(6182): 97–9.
468:
413:
370:
317:
316:
314:
311:
302:citrullination
297:
294:
269:
268:
265:
262:
259:
256:
252:
251:
246:
241:
236:
231:
177:
174:
137:
134:
103:citrullination
61:autoantibodies
27:Autoantibodies
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1771:
1760:
1757:
1756:
1754:
1739:
1736:
1734:
1731:
1730:
1728:
1724:
1716:
1713:
1711:
1708:
1707:
1706:
1705:
1701:
1700:
1694:
1691:
1689:
1686:
1685:
1683:
1680:
1679:
1676:
1673:
1671:
1670:Anti-thrombin
1668:
1667:
1665:
1663:Extracellular
1661:
1655:
1652:
1650:
1647:
1645:
1642:
1641:
1639:
1637:Cell membrane
1635:
1629:
1626:
1622:
1619:
1618:
1617:
1614:
1610:
1607:
1605:
1602:
1601:
1600:
1597:
1596:
1594:
1591:
1586:
1580:
1577:
1576:
1574:
1572:
1568:
1562:
1559:
1558:
1555:
1552:
1551:
1548:
1545:
1544:
1537:
1534:
1532:
1529:
1527:
1524:
1522:
1519:
1518:
1517:
1514:
1512:
1509:
1507:
1504:
1503:
1502:
1500:
1496:
1495:
1490:
1487:
1485:
1482:
1480:
1477:
1476:
1475:
1473:
1469:
1468:
1466:
1464:
1460:
1456:
1449:
1444:
1442:
1437:
1435:
1430:
1429:
1426:
1415:
1411:
1407:
1403:
1396:
1393:
1388:
1384:
1379:
1374:
1370:
1366:
1362:
1358:
1354:
1347:
1344:
1339:
1335:
1331:
1327:
1324:(5): 416–20.
1323:
1319:
1311:
1308:
1304:
1300:
1297:
1292:
1290:
1288:
1286:
1284:
1280:
1275:
1271:
1266:
1261:
1256:
1251:
1247:
1243:
1239:
1232:
1229:
1224:
1220:
1215:
1210:
1206:
1202:
1199:(7): 845–51.
1198:
1194:
1190:
1183:
1180:
1175:
1171:
1167:
1163:
1160:(10): 903–7.
1159:
1155:
1148:
1145:
1140:
1136:
1131:
1126:
1123:(8): 1590–3.
1122:
1118:
1114:
1107:
1104:
1099:
1095:
1091:
1087:
1083:
1079:
1075:
1071:
1064:
1061:
1048:
1044:
1040:
1036:
1032:
1028:
1021:
1018:
1013:
1009:
1005:
1001:
997:
993:
989:
985:
978:
975:
970:
966:
962:
958:
954:
950:
943:
940:
935:
931:
927:
923:
919:
915:
911:
907:
899:
896:
891:
887:
882:
877:
873:
869:
865:
858:
855:
850:
846:
841:
836:
832:
828:
824:
817:
814:
809:
805:
801:
797:
793:
789:
785:
781:
777:
773:
769:
768:
763:
756:
753:
748:
744:
740:
736:
732:
728:
724:
720:
713:
710:
706:
702:
697:
694:
689:
685:
681:
677:
673:
669:
662:
659:
654:
650:
646:
642:
639:(3): 733–41.
638:
634:
626:
623:
618:
614:
609:
604:
599:
594:
590:
586:
585:
580:
573:
571:
567:
562:
558:
553:
548:
544:
540:
537:(6): 2672–9.
536:
532:
528:
521:
518:
513:
509:
504:
499:
495:
491:
487:
483:
479:
472:
469:
464:
460:
456:
452:
447:
442:
439:(9): 1580–8.
438:
434:
427:
420:
418:
414:
409:
405:
401:
397:
393:
389:
386:(4): 339–63.
385:
381:
374:
371:
366:
362:
357:
352:
348:
344:
341:(2): 189–94.
340:
336:
332:
325:
323:
319:
312:
310:
308:
303:
295:
293:
291:
287:
282:
280:
276:
266:
263:
260:
257:
254:
253:
250:
247:
245:
242:
240:
237:
235:
232:
230:
227:
226:
223:
221:
216:
212:
210:
206:
202:
197:
195:
191:
187:
183:
175:
173:
171:
166:
163:
159:
154:
152:
147:
143:
135:
133:
131:
127:
123:
119:
114:
112:
108:
104:
100:
96:
92:
89:
84:
82:
78:
77:citrullinated
74:
70:
66:
62:
58:
54:
48:
44:
38:
34:
30:
19:
1714:
1702:
1693:Anti-gliadin
1561:Anti-histone
1497:
1470:
1405:
1401:
1395:
1360:
1356:
1346:
1321:
1317:
1310:
1245:
1241:
1231:
1196:
1192:
1182:
1157:
1153:
1147:
1120:
1116:
1106:
1076:(1): 46–51.
1073:
1069:
1063:
1051:. Retrieved
1047:the original
1034:
1031:J. Rheumatol
1030:
1020:
990:(1): 59–63.
987:
983:
977:
955:(3): 641–6.
952:
948:
942:
909:
905:
898:
871:
867:
857:
830:
826:
816:
771:
767:Rheumatology
765:
755:
722:
718:
712:
696:
671:
667:
661:
636:
632:
625:
588:
582:
534:
530:
520:
485:
481:
471:
436:
432:
383:
379:
373:
338:
335:Arch Med Sci
334:
299:
283:
272:
248:
243:
238:
233:
228:
217:
213:
198:
190:immunoassays
179:
169:
155:
139:
125:
115:
85:
56:
52:
51:
29:
1248:(6): R142.
912:: 295–303.
288:, 14-3-3η (
186:specificity
182:sensitivity
1621:Anti-actin
1554:Anti-dsDNA
1489:Anti-sp100
1479:Anti-gp210
868:J. Immunol
827:Clin. Chem
313:References
118:biomarkers
95:citrulline
65:antibodies
37:Citrulline
1590:cytoplasm
1526:Anti-nRNP
796:173280877
788:1462-0324
279:rituximab
146:filaggrin
75:that are
1753:Category
1649:Anti-GBM
1592:antibody
1511:Anti-Jo1
1484:Anti-p62
1414:25365087
1387:29628436
1338:24998790
1299:Archived
1274:19077182
1223:16606649
1139:20457731
1098:12677526
1090:25488711
1053:27 March
1043:17611988
1012:30850762
1004:12483219
934:12252627
926:16014545
890:16237041
849:17259232
808:Archived
804:17717033
739:17548411
688:17665451
653:16508937
617:15059278
482:Br Med J
455:20699241
400:17558653
365:22291756
229:Negative
165:isotypes
151:vimentin
107:antigens
99:vimentin
88:arginine
73:proteins
69:peptides
47:Arginine
1536:Anti-La
1531:Anti-Ro
1521:Anti-Sm
1378:6014894
1265:2656247
1214:1798205
1174:8402000
969:9500980
747:6640507
561:7539459
503:1596039
463:1191830
408:1773519
356:3258718
264:> 60
255:< 20
142:keratin
136:History
1609:P-ANCA
1604:C-ANCA
1412:
1385:
1375:
1336:
1272:
1262:
1221:
1211:
1172:
1137:
1096:
1088:
1041:
1010:
1002:
967:
932:
924:
888:
847:
802:
794:
786:
745:
737:
707:(MeSH)
686:
651:
615:
608:400433
605:
559:
552:295950
549:
512:111762
510:
500:
461:
453:
406:
398:
363:
353:
59:) are
1588:Anti-
1094:S2CID
1008:S2CID
930:S2CID
743:S2CID
459:S2CID
429:(PDF)
404:S2CID
307:YWHAH
290:YWHAH
261:40–59
258:20–39
205:ELISA
57:ACPAs
1516:ENA4
1410:PMID
1383:PMID
1334:PMID
1270:PMID
1219:PMID
1170:PMID
1135:PMID
1086:PMID
1055:2009
1039:PMID
1000:PMID
965:PMID
922:PMID
910:1050
886:PMID
845:PMID
800:PMID
792:OCLC
784:ISSN
735:PMID
684:PMID
649:PMID
613:PMID
557:PMID
508:PMID
451:PMID
396:PMID
361:PMID
249:Unit
218:The
160:and
144:and
71:and
1499:ENA
1472:PBC
1373:PMC
1365:doi
1326:doi
1260:PMC
1250:doi
1209:PMC
1201:doi
1162:doi
1125:doi
1078:doi
992:doi
957:doi
953:243
914:doi
876:doi
872:175
835:doi
776:doi
727:doi
723:146
676:doi
641:doi
603:PMC
593:doi
547:PMC
539:doi
498:PMC
490:doi
441:doi
388:doi
351:PMC
343:doi
267:EU
209:MCV
162:IgA
158:IgG
1755::
1704:RA
1684::
1406:32
1404:.
1381:.
1371:.
1361:25
1359:.
1355:.
1332:.
1322:81
1320:.
1282:^
1268:.
1258:.
1246:10
1244:.
1240:.
1217:.
1207:.
1197:65
1195:.
1191:.
1168:.
1158:32
1156:.
1133:.
1121:49
1119:.
1115:.
1092:.
1084:.
1074:18
1072:.
1035:34
1033:.
1029:.
1006:.
998:.
986:.
963:.
951:.
928:.
920:.
908:.
884:.
870:.
866:.
843:.
831:53
829:.
825:.
806:.
798:.
790:.
782:.
772:46
770:.
764:.
741:.
733:.
721:.
682:.
672:56
670:.
647:.
637:54
635:.
611:.
601:.
587:.
581:.
569:^
555:.
545:.
535:95
533:.
529:.
506:.
496:.
484:.
480:.
457:.
449:.
437:69
435:.
431:.
416:^
402:.
394:.
384:44
382:.
359:.
349:.
337:.
333:.
321:^
281:.
172:.
113:.
1501::
1474::
1447:e
1440:t
1433:v
1416:.
1389:.
1367::
1340:.
1328::
1276:.
1252::
1225:.
1203::
1176:.
1164::
1141:.
1127::
1100:.
1080::
1057:.
1014:.
994::
988:5
971:.
959::
936:.
916::
892:.
878::
851:.
837::
778::
749:.
729::
690:.
678::
655:.
643::
619:.
595::
589:6
563:.
541::
514:.
492::
486:2
465:.
443::
410:.
390::
367:.
345::
339:7
63:(
55:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
